Mortality due to cirrhosis and liver cancer in the United States, 1999-2016: observational study
Mortality due to cirrhosis and liver cancer in the United States, 1999-2016: observational study
复制标题
DOI：
10.1136/bm1k2817
复制
发表时间：
2018-07-18
影响因子：
105.7
通讯作者：
Parikh, Neehar D.
中科院分区：
文献类型：
--
作者：
Tapper, Elliot B.;Parikh, Neehar D.
目的按年龄组、性别、种族、肝病原因和地理区域描述 1999-2016 年美国肝病相关死亡率。设计观察性队列研究。设置来自生命统计合作社的死亡证明数据以及由疾病控制和预防中心流行病学研究广泛在线数据（1999-2016）汇编的美国人口普查局人口数据。参与者主要结果衡量肝硬化和肝细胞癌的死亡人数，并使用连接点回归评估趋势。结果从 1999 年到 2016 年，美国每年死于肝硬化的人数增加了 65%，达到 34 174 人，而每年死于肝细胞癌的人数翻了一番，达到 11 073 人。只有一个亚组（亚洲人和太平洋岛民）的死亡率有所改善肝细胞癌：死亡率下降2.7%（95%置信区间2.2%至3.3%，P
OBJECTIVETo describe liver disease related mortality in the United States during 1999-2016 by age group, sex, race, cause of liver disease, and geographic region.DESIGNObservational cohort study.SETTINGDeath certificate data from the Vital Statistics Cooperative, and population data from the US Census Bureau compiled by the Center for Disease Control and Prevention's Wide-ranging Online Data for Epidemiologic Research (1999-2016).PARTICIPANTSUS residents.MAIN OUTCOME MEASUREDeaths from cirrhosis and hepatocellular carcinoma, with trends evaluated using joinpoint regression.RESULTSFrom 1999 to 2016 in the US annual deaths from cirrhosis increased by 65%, to 34 174, while annual deaths from hepatocellular carcinoma doubled to 11 073. Only one subgroup-Asians and Pacific Islanders-experienced an improvement in mortality from hepatocellular carcinoma: the death rate decreased by 2.7% (95% confidence interval 2.2% to 3.3%, P